BrightSpring Health Services, Inc. (BTSG) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 137.50%. A quarter ago, it was expected that this company would post earnings of $0.19 per share when it actually produced earnings of $0.22, delivering a surprise of 15.79%.Over the last four qu ...

Core Insights - AirSculpt Technologies, Inc. reported first-quarter results for 2025, indicating a focus on returning to growth through strategic initiatives and cost management [1][2]. Financial Performance - Case volume for Q1 2025 was 3,076, a decline of 17.9% from 3,746 in Q1 2024 [6][22]. - Revenue decreased by 17.3% to $39.4 million from $47.6 million in the same quarter of the previous year [6][17]. - The company reported a net loss of $2.8 million compared to a net income of $6.0 million in Q1 2024 [6][17]. - Adjusted EBITDA was $3.8 million, down from $7.3 million in Q1 2024, with an adjusted EBITDA margin of 9.5% compared to 15.4% [6][22]. Strategic Initiatives - The CEO expressed confidence in the company's transformation efforts and highlighted the early benefits from a new go-to-market strategy, which has improved lead volumes and revenue decline [2]. - The company is focusing on increasing lead generation, consultations, and case conversions through enhanced marketing and sales efforts [2]. - AirSculpt is piloting a standalone skin tightening service, which has garnered increasing interest, positioning the company to capitalize on this opportunity [2]. Liquidity and Cash Flow - As of March 31, 2025, the company had $5.6 million in cash and cash equivalents, down from $8.2 million at the end of 2023 [5][19]. - Operating cash flow for Q1 2025 was $0.9 million, a decrease from $3.4 million in Q1 2024 [5][21]. 2025 Outlook - The company projects full-year 2025 revenue between $160 million and $170 million, with adjusted EBITDA guidance of approximately $16 million to $18 million [4][6].

Sotera Health Company (SHC) Q1 2025 Earnings Call May 01, 2025 09:00 AM ET Speaker0 Please also note that this event is being recorded. I would now like to turn the conference over to Vice President of Investor Relations and Treasurer, Jason Peterson. Jason, I turn the call over to you. Speaker1 Good morning and thank you. Welcome to Sotera Health's first quarter twenty twenty five earnings call. You can find today's press release and accompanying supplemental slides on the Investors section of our website ...

Core Viewpoint - Icon PLC reported quarterly earnings of $3.19 per share, exceeding the Zacks Consensus Estimate of $3.08 per share, but down from $3.47 per share a year ago, indicating a 8.1% year-over-year decline [1] - The company posted revenues of $2 billion for the quarter, missing the Zacks Consensus Estimate by 0.58% and down from $2.09 billion year-over-year, reflecting a 4.3% decrease [2] Group 1: Earnings Performance - Icon PLC achieved an earnings surprise of 3.57% for the recent quarter, having previously reported earnings of $3.43 per share against an expectation of $3.42 per share, resulting in a surprise of 0.29% [1][2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times [2] Group 2: Revenue Insights - The company has topped consensus revenue estimates only once in the last four quarters, indicating challenges in revenue performance [2] - The current consensus EPS estimate for the upcoming quarter is $3.25, with expected revenues of $2.05 billion, while the estimate for the current fiscal year is $13.48 on $8.21 billion in revenues [7] Group 3: Stock Performance and Outlook - Icon PLC shares have declined approximately 28.8% since the beginning of the year, contrasting with the S&P 500's decline of 5.5% [3] - The estimate revisions trend for Icon PLC is currently unfavorable, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [6] Group 4: Industry Context - The Medical Services industry, to which Icon PLC belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a relatively strong position within the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - CareDx reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and showing improvement from a loss of $0.03 per share a year ago, indicating a 50% earnings surprise [1] - The company posted revenues of $84.69 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.30%, but showing growth from $72.05 million year-over-year [2] Financial Performance - CareDx has surpassed consensus EPS estimates in all four of the last quarters, with a notable earnings surprise of 157.14% in the previous quarter [2][1] - The current consensus EPS estimate for the upcoming quarter is $0.13, with expected revenues of $90.31 million, and for the current fiscal year, the EPS estimate is $0.58 on revenues of $370.95 million [7] Market Position - CareDx shares have underperformed the market, losing approximately 15.3% since the beginning of the year, compared to a decline of 5.5% in the S&P 500 [3] - The Zacks Rank for CareDx is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Industry Outlook - The Medical Services industry, to which CareDx belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Wall Street expects a year-over-year decline in earnings on lower revenues when Charles River Laboratories (CRL) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on M ...

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 154.55%. A quarter ago, it was expected that this company would post earnings of $0.20 per share when it actually produced earnings of $0.70, delivering a surprise of 250%.Over the last four quarters, the company ...

Company Overview - Basel Medical Group Ltd has completed the acquisition of Bethesda Medical Pte. Ltd, enhancing its strategic expansion in Singapore and Southeast Asia's healthcare market [1][5] - Bethesda Medical, established in 1995, specializes in diagnostic imaging and outpatient care, and has a strong presence in both public and private healthcare sectors in Singapore [2] Strategic Integration - The acquisition solidifies the existing strategic partnership between Basel Medical Group and Bethesda Medical, allowing for deeper synergies and improved patient care [3] - The integration will create a seamless referral system between Basel Medical's orthopedic services and Bethesda Medical's diagnostic and outpatient services, particularly benefiting sport medicine and musculoskeletal injury cases [4] Market Positioning - This acquisition is part of Basel Medical Group's broader strategy to expand its service offerings and position itself as a key player in the evolving healthcare ecosystem in Southeast Asia [5] - Basel Medical Group has a robust business model supported by long-term relationships with corporations, particularly in construction, marine, and oil & gas industries, which positions it well for growth in the private healthcare sector [6]

Another stock in the Medical sector, Doximity (DOCS) , has outperformed the sector so far this year. The stock's year-to-date return is 6.2%. In Doximity's case, the consensus EPS estimate for the current year increased 13.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Coya Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 508 individual stocks and currently sits at #76 in the Zacks Industry Rank. Thi ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...